SipNose-topiramate: a potential novel approach to binge eating management

BACKGROUND: Binge-eating disorder) BED) is the most common eating disorder in the United-States. Daily, orally administered topiramate has shown BED treatment efficacy, with two major limitations: frequent and severe side effects and slow time-to-effect. SipNose is a novel non-invasive intranasal di...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobo-Greenhut, Ayala, Zohar-Beja, Adit, Hadar, Liron, Itzhaki, Lior, Karasik, Avraham, Caraco, Yoseph, Frankenthal, Hilel, Shahaf, Daniel, Ekstein, Dana, Shichor, Iris, Gur, Eitan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294342/
https://www.ncbi.nlm.nih.gov/pubmed/37365668
http://dx.doi.org/10.1186/s40337-023-00825-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294342/
https://www.ncbi.nlm.nih.gov/pubmed/37365668
http://dx.doi.org/10.1186/s40337-023-00825-9

Ejemplares similares